SHARE NOW
RenovoRx and Imugene announce their collaboration to explore Imugene’s CF33 oncolytic virus using RenovoRx’s proprietary trans-arterial micro-perfusion (TAMP™) platform for difficult-to-access tumors, such as pancreatic and liver tumors.
Clinical stage biopharmaceutical company, RenovoRx, Inc., RenovoRx, and clinical-stage immuno-oncology company, Imugene Ltd, Imugene, have announced their strategic research collaboration to optimize the delivery of Imugene’s oncolytic virus therapy with RenovoRx’s TAMP therapy platform for difficult-to-access tumors, such as pancreatic and liver tumors.
The unique approach of TAMP’s delivery system offers the potential to increase an oncology therapy’s efficacy, improve safety and broaden its therapeutic capabilities by focusing its distribution uniformly in target tissue. Traditional administration methods have been shown to limit therapy uptake due to dense fibrous tissue and lack of blood vessels supplying the tumors.
“Our collaboration with Imugene is an important milestone for RenovoRx as we expand our pipeline from exclusively treating locally advanced disease to treating metastatic disease with immunotherapy,” commented Shaun Bagai, CEO, RenovoRx. “We look forward to combining our proprietary TAMP platform with Imugene’s CF33 oncolytic virus with the goal of optimizing clinical benefits for patients.”
Imugene and RenovoRx will jointly investigate the ability to administer Imugene’s CF33 oncolytic virus technology with RenovoRx’s TAMP therapy platform. The TAMP platform is designed to deliver to a target tissue with precision. At the Society of Intervention Radiology 2019 Annual Meeting, a study was presented demonstrating a 100-fold (two orders of magnitude) increase in local tissue concentration with TAMP in comparison to conventional IV delivery. There were also advantages demonstrated compared to off-the-shelf intra-arterial (IA) delivery.
How are you enjoying this news article? Let us know your thoughts, here >>
“We believe the synergy between RenovoRx’s trans-arterial drug delivery system and our CF33 oncolytic virus platform has the potential to facilitate treatment of difficult-to-access cancers and help patients,” added Leslie Chong, Managing Director & CEO of Imugene.
Source: RenovoRx Press Release
While we have you…
We are continuously working to better optimize our content for you, our audience. Let us know how we’re doing by ticking the box below, or send us your feedback directly to team@phacilitate.com.
